Teva and Pfizer settle patent litigation over Celebrex


Israel-based Teva Pharmaceutical Industries says that its US subsidiary has settled a law suit with US…

Anti-Arthritics/RheumaticsCelebrexGenericsNorth AmericaPatentsPfizerTeva Pharmaceutical IndustriesUSA

Teva gains approval for generic Evista in the USA

Teva gains approval for generic Evista in the USA


Israel-based Teva Pharmaceutical Industries says it has received approval from the US Food and Drug Administration…

Anti-Arthritics/RheumaticsEli LillyEvistaGenericsNorth AmericaRegulationTeva Pharmaceutical IndustriesUSA

USPTO grants Pfizer reissue patent for Celebrex, extending term to Dec 2015


Global pharma behemoth Pfizer (NYSE: PFE) said yesterday that the US Patent & Trademark Office has granted…

Anti-Arthritics/RheumaticsApotexCelebrexGenericsLupinMylan LaboratoriesNorth AmericaPatentsPfizerPharmaceuticalTeva Pharmaceutical IndustriesWatson Pharmaceuticals

Amgen gains EU approval for Xgeva; Resolves G-CSF patent dispute with Teva


The European Commission has granted marketing authorization for US biotech giant Amgen’s (Nasdaq:…

AmgenAnti-Arthritics/RheumaticsEuropeGenericsNeupogenNeutrovalNorth AmericaOncologyPatentsPharmaceuticalRegulationTeva Pharmaceutical IndustriesXgeva

Court rejects Teva's motion to prevent Watson launch of generic Seasonique; nabumetone OKed; Mylan Copaxone judgment


US drugmaker Watson Pharmaceuticals (NYSE: WPI) confirmed on Friday that the US District Court for the…

Anti-Arthritics/RheumaticsCopaxoneGenericsLegalMylan LaboratoriesNabumetoneNeurologicalNorth AmericaRegulationSeasoniqueTeva Pharmaceutical IndustriesWatson Pharmaceuticals

AstraZeneca unit MedImmune in-licenses anti-inflammatory MAb from Amgen; latter’s Sensipar patent upheld


In a second deal in the space of a month for MedImmune, a US unit of Anglo-Swedish drug major AstraZeneca…

AmgenAnti-Arthritics/RheumaticsAstraZenecaBarr LaboratoriesLicensingMedImmuneOncologyPatentsPharmaceuticalSensiparTeva Pharmaceutical Industries

Back to top